Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This Phase Ia study aims to establish the maximum tolerated dose of once-weekly IV infused
PG545 and to evaluate its safety in subjects with advanced solid tumours. In addition, the
study will explore whether PG545 exposure results in changes to chemicals produced by the
body that are associated with cancer growth and spread.